Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10703798
APP PUB NO 20170107271A1
SERIAL NO

15301217

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Fusion polypeptides have an FGFR2 polypeptide and cDNAs encode such fusion polypeptides. Methods of diagnosing the presence of the fusion polypeptides or of a gene or RNA sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DEBIOPHARM INTERNATIONAL SA1006 LAUSANNE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Armenise, Claudia Eloise, FR 1 0
Chessex, Anne Vaslin Prilly, CH 1 0
Moulon, Corinne Saint-Légier, CH 4 2
Tanaka, Hiroaki Lausanne, CH 532 5487
Wojcik, Jérôme Divonne-les-Bains, FR 3 4

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 7, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 7, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00